Cotización GeneDx - WGS

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

71.10

Postura de Compra

70.68

Postura de Venta

72.49

Volume Operado de la Acción

134

0.00 Rango del Día 0.00

1.29 Rango de 52 semanas 89.1099

Capitalización de Mercado [m]

1.953B

Precio Anterior

71.10

Precio de Apertura

Hora

71.1

Última hora de negociación

07:16:37

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

590,725

Acciones en circulación

27,471,397

Rendimiento del Dividendo

Ratio Precio/Utilidad

-11.11

Beneficio por acción (BPA)

-6.4

turnover

202.57M

Beneficio neto

-175.77M

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Companyâ¿¿s segments are GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and ra... GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Companyâ¿¿s segments are GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and womenâ¿¿s health and somatic oncology diagnostic testing and screening products. Mostrar más

Sector

Blank Checks

Industria

Health Services

Sitio web

www.genedx.com

Sede

Wilmington, Delaware, USA

Fundado

2020

GeneDx Holdings Corporation is listed in the Blank Checks sector of the NASDAQ with ticker WGS. The last closing price for GeneDx was US$71.10. Over the last year, GeneDx shares have traded in a share price range of US$ 1.29 to US$ 89.1099.

GeneDx currently has 27,471,397 shares in issue. The market capitalisation of GeneDx is US$1.95 billion. GeneDx has a price to earnings ratio (PE ratio) of -11.11.

Flujo General

Optimista

Prima Neta

118k

Calls / Puts

100.00%

Comp. / Vent.

50.00%

OTM / ITM

200.00%

Sweeps Ratio

0.00%

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today...

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (Nasdaq: WGS), a leader in delivering improved health...

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white...

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility GeneDx (Nasdaq: WGS), a leader in delivering...

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test...

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-1.75	-2.40219629375	72.85	82.181	66	643780	73.63428218	CS
4	13.14	22.6708074534	57.96	89.1099	55.3	774552	75.73738119	CS
12	35.77	101.245400509	35.33	89.1099	28.86	590725	58.85730726	CS
26	49.5	229.166666667	21.6	89.1099	19.16	479649	46.55926929	CS
52	69.5	4343.75	1.6	89.1099	1.29	449323	29.55166289	CS
156	60.177	550.920076902	10.923	89.1099	1.16	971932	16.67234196	CS
260	60.177	550.920076902	10.923	89.1099	1.16	971932	16.67234196	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
PRFXPainReform Ltd	US$ 1.42 (165.42%)	43.68M
NCNCnoco noco Inc	US$ 0.2474 (155.05%)	191.17M
TRNRInteractive Strength Inc	US$ 4.12 (62.85%)	12.72M
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 38.80 (52.04%)	469.4k
BCALCalifornia BanCorp	US$ 24.01 (39.51%)	235
CBLLCeriBell Inc	US$ 12.11 (-51.56%)	111
XNCRXencor Inc	US$ 14.11 (-39.15%)	25
MBXMBX Biosciences Inc	US$ 10.01 (-39.04%)	1
UPBUpstream Bio Inc	US$ 14.51 (-38.96%)	107
ECBKECB Bancorp Inc	US$ 10.01 (-33.31%)	14
NCNCnoco noco Inc	US$ 0.2474 (155.05%)	191.17M
PRFXPainReform Ltd	US$ 1.42 (165.42%)	43.68M
HCWBHCW Biologics Inc	US$ 1.54 (24.19%)	20.77M
TFFPTFF Pharmaceuticals Inc	US$ 0.4201 (15.41%)	20.06M
SMCISuper Micro Computer Inc	US$ 27.13 (25.95%)	18.55M